Key Strategic Developments and Emerging Changes Shaping the Dengue Vaccine Market Landscape

The dengue vaccine market is on track for significant expansion in the coming years, driven by advances in vaccine development and increasing public health initiatives. As global efforts intensify to curb dengue infections, the market dynamics are evolving rapidly, with new players and novel vaccine technologies shaping the landscape. Let's explore the market's projected growth, key companies, emerging trends, and the main segments influencing this vital healthcare sector.

Forecasted Market Value of the Dengue Vaccine Market by 2030
The dengue vaccine market is anticipated to grow swiftly, reaching a valuation of $1.16 billion by 2030. This growth corresponds to a compound annual growth rate (CAGR) of 17.3%. The expected rise is supported by several factors such as the expansion of immunization programs worldwide, increasing investments in vaccine research, and higher healthcare expenditure in regions where dengue is endemic. Additionally, a stronger emphasis on the effectiveness of vaccines targeting multiple dengue strains, along with faster regulatory approvals, will play a crucial role in propelling the market forward. Prominent market trends during this period include a stronger global commitment to dengue prevention, the expansion of government-led vaccination drives, increased adoption of tetravalent dengue vaccines, enhanced public health funding in affected regions, and growing demand for pediatric immunization solutions.

Download a free sample of the dengue vaccine market report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=19026&type=smp

Key Market Participants Leading the Dengue Vaccine Industry
The dengue vaccine market features several prominent companies driving innovation and production, including Merck & Co. Inc., Sanofi Pasteur Limited, GlaxoSmithKline plc, Takeda Pharmaceutical Company, Biological E. Limited, Saint Louis University, Indian Immunologicals Limited, Serum Institute of India Pvt. Ltd., Bavarian Nordic, Instituto Butantan, Bharat Biotech Ltd., Panacea Biotec Limited, SABIN Vaccine Institute, Medigen Vaccine Biologics Corporation, Emergex Vaccines Holding Ltd., BioNet-Asia Co. Ltd., Codagenix Inc., KM Biologics Co. Ltd., Chula Vaccine Research Center, and Imutex Ltd.

Strategic Partnership Enhancing Dengue Vaccine Production
In February 2024, Takeda Pharmaceutical Company, a Japan-based dengue vaccine manufacturer, entered a partnership with Biological E. Limited, an Indian biotechnology and biopharmaceutical firm. This collaboration aims to boost the production and availability of Takeda's QDENGA (TAK-003) vaccine in dengue-endemic countries. By increasing manufacturing capacity and supplying multi-dose vials, the partnership supports national immunization programs, making the vaccine more accessible to populations at risk.

View the full dengue vaccine market report:
https://www.thebusinessresearchcompany.com/report/dengue-vaccine-global-market-report

Emerging Trends Shaping the Future of the Dengue Vaccine Market
Leading companies in the dengue vaccine sector are prioritizing clinical trials aimed at developing innovative vaccines, particularly live attenuated formulations designed to provide broad and lasting protection against all four dengue virus serotypes. Live attenuated vaccines use a weakened form of the virus, which cannot cause disease but stimulates a strong immune response. This approach enables the body to recognize and combat the actual virus effectively upon exposure.

For example, in June 2025, Merck & Co. Inc., a US-based pharmaceutical firm, began the MOBILIZE-1 Phase 3 clinical trial to test V181, its investigational live attenuated tetravalent dengue vaccine. The trial plans to enroll around 12,000 healthy children and adolescents aged 2 to 17 across dengue-endemic Asia-Pacific countries, including Indonesia, Malaysia, the Philippines, Singapore, Thailand, and Vietnam. The study is designed as a randomized, double-blind, placebo-controlled trial assessing the safety, immune response, and effectiveness of a single V181 dose against all four dengue virus types, regardless of previous dengue exposure. The vaccine aims to protect against symptomatic dengue of any severity, including severe cases necessitating hospitalization, with the goal of significantly reducing the global impact of this rapidly spreading mosquito-borne illness.

Detailed Segment Analysis of the Dengue Vaccine Market
This report breaks down the dengue vaccine market into several key segments:
1) By Type: Live Attenuated Vaccine, Chimeric Live Attenuated Vaccine, Inactivated Vaccine, Subunit Vaccine, Nucleic Acid Based Vaccine
2) By Vaccine Phase: Phase I, Phase II, Phase III
3) By Route Of Administration: Oral, Parenteral, Other Routes
4) By End-User: Hospitals, Clinics, Government Institutes, Non-Governmental Organizations, Other End-Users

Further subcategories include:
- Live Attenuated Vaccine: Single Strain, Multi-Strain
- Chimeric Live Attenuated Vaccine: Tetravalent Chimeric Vaccine, Monovalent Chimeric Vaccine
- Inactivated Vaccine: Whole Virus Inactivated Vaccine, Split Virus Vaccine
- Subunit Vaccine: Recombinant Protein Vaccine, Peptide-Based Vaccine
- Nucleic Acid Based Vaccine: DNA Vaccine, mRNA Vaccine

This comprehensive segmentation provides a clear understanding of the market's structure and highlights diverse vaccine types and applications that will influence future growth and innovation in the dengue vaccine industry.

Reach out to us:
The Business Research Company: https://www.thebusinessresearchcompany.com/,
Americas +1 310-496-7795,
Europe +44 7882 955267,
Asia & Others +44 7882 955267 & +91 8897263534,
Email us at info@tbrc.info.

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Learn More About The Business Research Company
With over 17500+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.Our flagship product, the Global Market Model (GMM), is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.